Hypocretin (orexin) deficiency in human narcolepsy

Lancet

Volumn 355, Issue 9197, 2000, Pages 39-40

  Nishino, Seiji ^a   Ripley, Beth ^a   Overeem, Sebastiaan ^a   Lammers, Gert Jan ^b   Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; METHYLPHENIDATE; MODAFINIL; NEUROPEPTIDE RECEPTOR; OREXIN;

ADULT; AGED; ARTICLE; CATAPLEXY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; INFORMED CONSENT; MALE; NARCOLEPSY; NEUROTRANSMISSION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0033971611     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)05582-8     Document Type: Article

References (5)

1. Nishino S., Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 52:1997;27-78.
2. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 50:1998;16-22. (suppl 1).
3. Lin L., Faraco J., Li R.et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 98:1999;365-376.
4. Chemelli R.M., Willie J.T., Sinton C.M.et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 98:1999;437-451.
5. Peyron C., Tighe D.K., van den Pol A.N.et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 18:1998;9996-10015.